NorthSea Therapeutics

NorthSea Therapeutics: First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. Lead candidate Icosabutate for NASH; positive Ph 2b interim data announced Jan. 21 shows highly statistically significant reductions in major biomarkers impacting NASH resolution and fibrosis. Pipeline includes SEFA-1024 (Ph1, dyslipidemia) and late-stage preclinical Parenteral Nutrition Associated Liver Disease (PNALD) program. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments - funds completion of Ph 2b ICONA study in NASH.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Other
Clinical Stage
Phase l or ll
Finance
Pre-earnings
Industry
Biotechnology
Investment Participation
CrossOvers
Listing
Private
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
Gooimeer 2 35
Naarden, Noord-Holland 1411 DC
The Netherlands

Company Participants at NorthSea Therapeutics NASH Virtual KOL Call with Dr. John Kastelein

  • Rob de Ree, Chief Executive Officer & Board Member